Cargando…

Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases

To date, there is no clear agreement regarding which is the best method to detect a connective tissue disease (CTD) during the initial diagnosis of interstitial lung diseases (ILD). The aim of our study was to explore the impact of a systematic diagnostic strategy to detect CTD-associated ILD (CTD-I...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez-Gonzalez, Fernanda, Prieto-González, Sergio, Brito-Zeron, Pilar, Cuerpo, Sandra, Sanchez, Marcelo, Ramirez, Jose, Agustí, Carlos, Lucena, Carmen María, Paradela, Marina, Grafia, Ignacio, Espinosa, Gerard, Sellares, Jacobo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004576/
https://www.ncbi.nlm.nih.gov/pubmed/31977850
http://dx.doi.org/10.1097/MD.0000000000018589
_version_ 1783494753940144128
author Hernandez-Gonzalez, Fernanda
Prieto-González, Sergio
Brito-Zeron, Pilar
Cuerpo, Sandra
Sanchez, Marcelo
Ramirez, Jose
Agustí, Carlos
Lucena, Carmen María
Paradela, Marina
Grafia, Ignacio
Espinosa, Gerard
Sellares, Jacobo
author_facet Hernandez-Gonzalez, Fernanda
Prieto-González, Sergio
Brito-Zeron, Pilar
Cuerpo, Sandra
Sanchez, Marcelo
Ramirez, Jose
Agustí, Carlos
Lucena, Carmen María
Paradela, Marina
Grafia, Ignacio
Espinosa, Gerard
Sellares, Jacobo
author_sort Hernandez-Gonzalez, Fernanda
collection PubMed
description To date, there is no clear agreement regarding which is the best method to detect a connective tissue disease (CTD) during the initial diagnosis of interstitial lung diseases (ILD). The aim of our study was to explore the impact of a systematic diagnostic strategy to detect CTD-associated ILD (CTD-ILD) in clinical practice, and to clarify the significance of interstitial pneumonia with autoimmune features (IPAF) diagnosis in ILD patients. Consecutive patients evaluated in an ILD Diagnostic Program were divided in 3 groups: IPAF, CTD-ILD, and other ILD forms. Clinical characteristics, exhaustive serologic testing, high resolution computed tomography (HRCT) images, lung biopsy specimens, and follow-up were prospectively collected and analyzed. Among 139 patients with ILD, CTD was present in 21 (15.1%), 24 (17.3%) fulfilled IPAF criteria, and 94 (67.6%) were classified as other ILD forms. Specific systemic autoimmune symptoms such as Raynaud phenomenon (19%), inflammatory arthropathy (66.7%), and skin manifestations (38.1%) were more frequent in CTD-ILD patients than in the other groups (all P < .001). Among autoantibodies, antinuclear antibody was the most frequently found in IPAF (42%), and CTD-ILD (40%) (P = .04). Nonspecific interstitial pneumonia, detected by HRCT scan, was the most frequently seen pattern in patients with IPAF (63.5%), or CTD-ILD (57.1%) (P < .001). In multivariate analysis, a suggestive radiological pattern by HRCT scan (odds ratio [OR] 15.1, 95% confidence interval [CI] 4.7–48.3, P < .001) was the strongest independent predictor of CTD-ILD or IPAF, followed by the presence of clinical features (OR 14.6, 95% CI 4.3–49.5, P < .001), and serological features (OR 12.4, 95% CI 3.5–44.0, P < .001). This systematic diagnostic strategy was useful in discriminating an underlying CTD in patients with ILD. The defined criteria for IPAF are fulfilled by a considerable proportion of patients referred for ILD.
format Online
Article
Text
id pubmed-7004576
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-70045762020-02-18 Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases Hernandez-Gonzalez, Fernanda Prieto-González, Sergio Brito-Zeron, Pilar Cuerpo, Sandra Sanchez, Marcelo Ramirez, Jose Agustí, Carlos Lucena, Carmen María Paradela, Marina Grafia, Ignacio Espinosa, Gerard Sellares, Jacobo Medicine (Baltimore) 6700 To date, there is no clear agreement regarding which is the best method to detect a connective tissue disease (CTD) during the initial diagnosis of interstitial lung diseases (ILD). The aim of our study was to explore the impact of a systematic diagnostic strategy to detect CTD-associated ILD (CTD-ILD) in clinical practice, and to clarify the significance of interstitial pneumonia with autoimmune features (IPAF) diagnosis in ILD patients. Consecutive patients evaluated in an ILD Diagnostic Program were divided in 3 groups: IPAF, CTD-ILD, and other ILD forms. Clinical characteristics, exhaustive serologic testing, high resolution computed tomography (HRCT) images, lung biopsy specimens, and follow-up were prospectively collected and analyzed. Among 139 patients with ILD, CTD was present in 21 (15.1%), 24 (17.3%) fulfilled IPAF criteria, and 94 (67.6%) were classified as other ILD forms. Specific systemic autoimmune symptoms such as Raynaud phenomenon (19%), inflammatory arthropathy (66.7%), and skin manifestations (38.1%) were more frequent in CTD-ILD patients than in the other groups (all P < .001). Among autoantibodies, antinuclear antibody was the most frequently found in IPAF (42%), and CTD-ILD (40%) (P = .04). Nonspecific interstitial pneumonia, detected by HRCT scan, was the most frequently seen pattern in patients with IPAF (63.5%), or CTD-ILD (57.1%) (P < .001). In multivariate analysis, a suggestive radiological pattern by HRCT scan (odds ratio [OR] 15.1, 95% confidence interval [CI] 4.7–48.3, P < .001) was the strongest independent predictor of CTD-ILD or IPAF, followed by the presence of clinical features (OR 14.6, 95% CI 4.3–49.5, P < .001), and serological features (OR 12.4, 95% CI 3.5–44.0, P < .001). This systematic diagnostic strategy was useful in discriminating an underlying CTD in patients with ILD. The defined criteria for IPAF are fulfilled by a considerable proportion of patients referred for ILD. Wolters Kluwer Health 2020-01-24 /pmc/articles/PMC7004576/ /pubmed/31977850 http://dx.doi.org/10.1097/MD.0000000000018589 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 6700
Hernandez-Gonzalez, Fernanda
Prieto-González, Sergio
Brito-Zeron, Pilar
Cuerpo, Sandra
Sanchez, Marcelo
Ramirez, Jose
Agustí, Carlos
Lucena, Carmen María
Paradela, Marina
Grafia, Ignacio
Espinosa, Gerard
Sellares, Jacobo
Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases
title Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases
title_full Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases
title_fullStr Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases
title_full_unstemmed Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases
title_short Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases
title_sort impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases
topic 6700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004576/
https://www.ncbi.nlm.nih.gov/pubmed/31977850
http://dx.doi.org/10.1097/MD.0000000000018589
work_keys_str_mv AT hernandezgonzalezfernanda impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT prietogonzalezsergio impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT britozeronpilar impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT cuerposandra impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT sanchezmarcelo impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT ramirezjose impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT agusticarlos impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT lucenacarmenmaria impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT paradelamarina impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT grafiaignacio impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT espinosagerard impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases
AT sellaresjacobo impactofasystematicevaluationofconnectivetissuediseaseondiagnosisapproachinpatientswithinterstitiallungdiseases